Literature DB >> 18466083

Use of capecitabine in refractory metastatic medullary thyroid carcinoma.

Carlos Eduardo Paiva, Odair Carlito Michelin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18466083     DOI： 10.1089/thy.2007.0220

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


× No keyword cloud information.
  4 in total

Review 1.  Occult primary medullary thyroid carcinoma presenting with pituitary and parotid metastases: case report and review of the literature.

Authors:  Andrea Conway; Andres Wiernik; Ajay Rawal; Cornelius Lam; Hector Mesa
Journal:  Endocr Pathol       Date:  2012-06       Impact factor: 3.943

Review 2.  Medullary thyroid cancer--current treatment strategy, novel therapies and perspectives for the future.

Authors:  Masahiro Sugawara; Tran Ly; Jerome M Hershman
Journal:  Horm Cancer       Date:  2012-08-04       Impact factor: 3.869

Review 3.  Medical management of metastatic medullary thyroid cancer.

Authors:  Jessica E Maxwell; Scott K Sherman; Thomas M O'Dorisio; James R Howe
Journal:  Cancer       Date:  2014-06-18       Impact factor: 6.860

Review 4.  Targeted Therapy for Medullary Thyroid Cancer: A Review.

Authors:  S R Priya; Chandra Shekhar Dravid; Raghunadharao Digumarti; Mitali Dandekar
Journal:  Front Oncol       Date:  2017-10-06       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.